2026年美国临床肿瘤学会（ASCO）年会将于5月29日至6月3日在美国芝加哥举行。作为全球规模最大的肿瘤学研究盛会之一，此次大会云集全球肿瘤学领域的顶尖专家学者，共同探讨和分享最新的研究成果、治疗方法和临床实践经验。目前大会官网已公布摘要标题，【肿瘤资讯】特此整理了本届大会中肺癌领域的重磅口头报告（Oral, Rapid Oral）的最新研究成果，以飨诸君。
Plenary Session
摘要号：LBA3
英文标题：Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
中文标题：Ⅲ期LIBRETTO-432研究主要结果：塞普替尼辅助治疗RET融合阳性IB-IIIA期非小细胞肺癌的无事件生存获益
讲者：Jonathan Goldman
单位：University of California Los Angeles, Los Angeles, CA
摘要号：LBA4
英文标题：Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
中文标题：Ⅲ期HARMONi-6研究总生存结果：依沃西单抗联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌
讲者：陆舜
单位：上海交通大学医学院附属胸科医院
Oral Abstract Session
Lung Cancer-Non-Small Cell Metastatic
摘要号：LBA8500
英文标题：Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
中文标题：WU-KONG28研究主要分析：舒沃替尼单药对比含铂化疗一线治疗EGFR exon20ins晚期非小细胞肺癌的疗效与安全性
讲者：John Heymach
单位：Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
摘要号：8501
英文标题：Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
中文标题：CHRYSALIS-2研究一线亚组更新结果：埃万妥单抗联合兰泽替尼治疗非典型EGFR突变晚期非小细胞肺癌的总生存结果
讲者：Joel Neal
单位：Stanford Cancer Institute, Stanford University, Stanford, CA
摘要号：8502
英文标题：Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
中文标题：Ⅲ期CROWN研究7年更新结果：洛拉替尼对比克唑替尼一线治疗晚期ALK阳性非小细胞肺癌
讲者：Tony Mok
单位：香港中文大学
摘要号：8503
英文标题：ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
中文标题：ALKOVE-1研究：奈拉达替尼治疗晚期ALK阳性非小细胞肺癌患者的疗效与安全性
讲者： Jessica Lin
单位： Mass General Brigham Cancer Institute, Boston, MA
摘要号：8504
英文标题：Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
中文标题：Ⅲ期AcceleRET-Lung研究：普拉替尼一线治疗RET融合阳性晚期或转移性非小细胞肺癌的疗效与安全性
讲者：Sanjay Popat
单位：Royal Marsden Hospital & Institute of Cancer Research, London, United Kingdom
摘要号：8505
英文标题：Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).
中文标题：关键性Ⅱ期研究结果：下一代选择性RET抑制剂lunbotinib（A400/EP0031）治疗晚期RET融合阳性非小细胞肺癌患者的疗效与安全性
讲者：周清
单位：广东省人民医院
摘要号：8506
英文标题：Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
中文标题：OptiTROP-Lung05研究结果：芦康沙妥珠单抗联合帕博利珠单抗对比帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌
讲者：周彩存
单位：同济大学附属东方医院
摘要号：LBA8507
英文标题：A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non–small cell lung cancer.
中文标题：一项随机、开放标签、平行对照的Ⅲ期研究：贝莫苏拜单抗联合化疗及安罗替尼一线治疗晚期非鳞状非小细胞肺癌
讲者：石远凯
单位：国家癌症中心
摘要号：8624
英文标题：Wait or treat? managing asymptomatic brain metastases in oncogene-mutated NSCLC: Results of a phase-III randomized controlled trial.
中文标题：等待还是治疗？驱动基因突变非小细胞肺癌无症状脑转移的管理：一项Ⅲ期随机对照研究结果
讲者：Anil Tibdewal
单位：Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Lung Cancer-Non-Small Cell Local-Regional/SmallCell/Other Thoracic Cancers
摘要号：8000
英文标题：Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
中文标题：ECOG-ACRIN EA5142（ALCHEMIST）Ⅲ期随机研究：纳武利尤单抗用于非小细胞肺癌术后辅助化疗后治疗
讲者：Jamie Chaft
单位：Memorial Sloan Kettering Cancer Center, New York, NY
摘要号：8001
英文标题：Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105.
中文标题：Alliance A081105最终总生存结果：EGFR突变非小细胞肺癌完全切除术后厄洛替尼辅助治疗对比观察
讲者：Ramaswamy Govindan
单位：Alvin J Siteman Cancer Center at Washington University School of Medicine in St. Louis, St. Louis, MO
摘要号：8002
英文标题：Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN).
中文标题：LORIN研究：洛拉替尼新辅助治疗ALK融合阳性Ⅲ期非小细胞肺癌的多中心Ⅱ期研究
讲者：待定
摘要号：8003
英文标题：Pollution and progression: Air quality and stage of lung cancer diagnosis across the U.S.
中文标题：污染与进展：全美空气质量与肺癌诊断分期的相关性
讲者：待定
摘要号：8004
英文标题：Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.
中文标题：重定义肺癌筛查适用人群：基于全国VA近100万例患者队列比较吸烟年限与包年数的价值
讲者：Brendan Heiden
单位：Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
摘要号：LBA8005
英文标题：Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase IIl trial.
中文标题：广泛期小细胞肺癌Ⅱ期研究：同步胸部放疗联合铂类/依托泊苷化疗及度伐利尤单抗免疫治疗
讲者：Bjorn Henning Gronberg
单位：Department of Oncology, St. Olavs hospital,Trondheim, Norway
摘要号：8006
英文标题：Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
中文标题：DeLLphi-304 Ⅲ期研究事后分析：塔拉妥单抗对比化疗二线治疗小细胞肺癌的颅内疗效
讲者：Giannis Mountzios
单位：Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece
摘要号：8007
英文标题：Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, phase 2 study.
中文标题：多中心Ⅱ期研究：依沃西单抗联合脂质体伊立替康治疗一线免疫联合化疗后进展的小细胞肺癌患者的疗效与安全性
讲者：范云
单位：浙江省肿瘤医院
摘要号：8008
英文标题：ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).
中文标题：ABBV-706单药及联合budigalimab治疗复发/难治性小细胞肺癌患者的研究结果
讲者：Lauren Byers
单位：The University of Texas MD Anderson Cancer Center, Houston, TX
Rapid Oral Abstract Session
Lung Cancer-Non-Small Cell Metastatic
摘要号：8512
英文标题：Efficacy and safety of HLX43 (anti–PD-L1 ADC) in patients with advanced non–small cell lung cancer.
中文标题：HLX43（抗PD-L1 ADC）治疗晚期非小细胞肺癌患者的疗效与安全性。
讲者：王洁
单位：中国医学科学院肿瘤医院
摘要号：8513
英文标题：Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC.
中文标题：ROSETTA Lung-02全球随机Ⅱ/Ⅲ期研究Ⅱ期数据：pumitamig（PD-L1×VEGF-A双特异性抗体）联合化疗一线治疗非小细胞肺癌
讲者：Solange Peters
单位：Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland
摘要号：8514
英文标题：Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
中文标题：Ⅱ期研究更新结果：SSGJ-707（PF-08634404，一种PD-1/VEGF双特异性抗体）单药治疗晚期非小细胞肺癌患者
讲者：邬麟
单位：湖南省肿瘤医院
摘要号：8515
英文标题：Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.
中文标题：TRITON研究Ⅱb期中期分析：Tremelimumab联合度伐利尤单抗及化疗对比帕博利珠单抗联合化疗一线治疗伴STK11、KEAP1和/或KRAS突变的非鳞状转移性非小细胞肺癌
讲者：Ferdinandos Skoulidis
单位：The University of Texas MD Anderson Cancer Center, Houston, TX
摘要号：8516
英文标题：A phase 1/2 study of TSN1611, a highly selective oral KRAS G12D inhibitor, in solid tumors: Efficacy and safety in KRAS G12D–mutated NSCLC patients.
中文标题：实体瘤Ⅰ/Ⅱ期研究：高选择性口服KRAS G12D抑制剂TSN1611在KRAS G12D突变非小细胞肺癌患者中的疗效与安全性
讲者： 虞永峰
单位：上海交通大学医学院附属胸科医院
摘要号：8517
英文标题：Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial.
中文标题：ARCHER研究主要分析：靶向耐药突变的预防性肽疫苗用于晚期ALK阳性肺癌
讲者：Vincent K. Lam
单位：Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD
摘要号：LBA8518
英文标题：Phase 3 clinical trial of the combination of erlotinib plus ramucirumab compared with osimertinib in untreated advanced or recurrent non-small cell lung cancer with EGFR L858R mutation: The REVOL858R trial (WJOG14420L).
中文标题：REVOL858R（WJOG14420L）Ⅲ期研究：厄洛替尼联合雷莫芦单抗对比奥希替尼治疗未经治疗的晚期或复发性EGFR L858R突变非小细胞肺癌
讲者：Naoki Haratake
单位：Department of Thoracic Oncology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan
摘要号：8519
英文标题：Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
中文标题：Ⅱ期研究安全性与疗效结果：silevertinib（BDTX-1535）治疗初治非经典EGFR突变非小细胞肺癌患者
讲者：Julia Rotow
单位：Dana-Farber Cancer Institute, Boston, MA
摘要号：8520
英文标题：DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with EGFR C797X mutations: Results from phase 1/2 studies.
中文标题：Ⅰ/Ⅱ期研究结果：第四代EGFR TKI DZD6008治疗经治EGFR C797X突变非小细胞肺癌患者
讲者：王孟昭
单位：北京协和医院
Lung Cancer-Non-Small Cell Local-Regional/SmallCell/Other Thoracic Cancers
摘要号：8009
英文标题：Complex segmentectomy versus lobectomy in small-sized peripheral non–small cell lung cancer: A post-hoc supplemental analysis of a multicenter, open-label, phase 3 trial (JCOG0802/WJOG4607L).
中文标题：JCOG0802/WJOG4607L多中心开放标签Ⅲ期研究事后补充分析：复杂肺段切除对比肺叶切除治疗小型周围型非小细胞肺癌
讲者：Atsushi Kamigaichi
单位：Hiroshima University, Hiroshima, Japan
摘要号：8010
英文标题：Perioperative toripalimab in non-small cell lung cancer: Clinical outcomes and safety from a large prospective real-world study.
中文标题：大型前瞻性真实世界研究：特瑞普利单抗围手术期治疗非小细胞肺癌的临床结局与安全性
讲者：宋平平
单位：山东第一医科大学附属肿瘤医院
摘要号：8011
英文标题：LuSato-1: Phase I study of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in patients with extensive stage small cell lung cancer (ES-SCLC) on maintenance treatment with immune checkpoint inhibition (ICI).
中文标题：LuSato-1：177Lu-SSO110联合68Ga-SSO120伴随显像在接受免疫检查点抑制剂维持治疗的广泛期小细胞肺癌患者中的Ⅰ期研究
讲者：Surein Arulananda
单位：Monash Health, Clayton, VIC, Australia
摘要号：8012
英文标题：Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.
中文标题：正在进行的Ⅰ期研究初步结果：LB2102（一种经dnTGFBR2修饰的DLL3靶向自体CAR-T细胞疗法）治疗复发/难治性小细胞肺癌或大细胞神经内分泌癌患者
讲者：Zhonglin Hao
单位：Markey Cancer Center, Lexington, KY
摘要号：8013
英文标题：Autologous natural killer cell infusion as consolidation therapy after first-line chemoradiotherapy for limited-stage small-cell lung cancer: A randomized, controlled, open-label, single-center phase II clinical study.
中文标题：随机对照、开放标签、单中心Ⅱ期临床研究：自体自然杀伤细胞输注作为局限期小细胞肺癌一线放化疗后的巩固治疗
讲者：崔久嵬
单位：吉林大学第一医院
摘要号：8014
英文标题：Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).
中文标题：IMforte Ⅲ期研究：芦比替定联合阿替利珠单抗维持治疗广泛期小细胞肺癌的分子亚型转录组学分析及其与临床结局的相关性
讲者：Luis Paz-Ares
单位：Hospital Universitario 12 de Octubre, Universidad Complutense and Ciberonc, Madrid, Spain
摘要号：8015
英文标题：Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
中文标题：AEGEANⅢ期研究：新辅助度伐利尤单抗对可切除非小细胞肺癌患者肿瘤微环境特征的影响及其与无事件生存的相关性
讲者：John Heymach
单位：Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
摘要号：8016
英文标题：Tumor-naïve multimodal cfDNA MRD assay to predict recurrence in a prospective cohort of patients undergoing curative-intent lung cancer resection.
中文标题：在初治肺癌患者中采用多模式 cfDNA 微小残留病灶检测预测根治性切除术后复发风险：一项前瞻性队列研究
讲者：卢笛
单位：南方医科大学南方医院
摘要号：8017
英文标题：Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer.
中文标题：超高灵敏度单个位数百万分率ctDNA检测在非小细胞肺癌中的临床效度
讲者：待定
注：如有任何错漏，敬请指正！
排版编辑：肿瘤资讯-Nydia
苏公网安备32059002004080号
